This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Buying shares of the right companies -- those that can generate generous returns for decades -- will help significantly ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results , with sales up 5.6% year on year to $15.1 billion. Its ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie has an impressive portfolio of assets. The company has a market cap of more than $300 billion, massive growth since it was spun-off from Abbott Laboratories. At the same time, it's more ...

Regarding distributions, we view AbbVie’s dividends and share repurchases as about right. Since being divested from Abbott, AbbVie has largely focused on a dividend payout ratio close to 50% ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...